Dopamine Hydrochloride and Dextrose 320 mg/100mL

Dopamine Hydrochloride · INJECTION, SOLUTION · Baxter Healthcare Corporation

No Recall HistoryCurrently in Shortage

Plain English

Dopamine Hydrochloride and Dextrose is a injection, solution containing dopamine hydrochloride at 320 mg/100mL, taken intravenous. Manufactured by Baxter Healthcare Corporation.

Key Facts

Brand Name: Dopamine Hydrochloride and Dextrose
Generic Name: Dopamine Hydrochloride
NDC Code (Product): 0338-1009
Manufacturer: Baxter Healthcare Corporation
Strength: 320 mg/100mL
Dosage Form: INJECTION, SOLUTION
Route: INTRAVENOUS
Marketing Status
Application #: NDA019615
Marketing Start: 03/27/1987

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

drug ineffective51 reports

hypotension50 reports

pneumonia46 reports

platelet count decreased45 reports

pyrexia44 reports

renal impairment41 reports

blood pressure decreased38 reports

cardiac failure36 reports

condition aggravated36 reports

cardiac arrest35 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE Dopamine hydrochloride is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in congestive failure. Where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine hydrochloride. Patients most likely to respond adequately to dopamine hydrochloride are those in whom physiological parameters, such as urine flow, myocardial function and blood pressure have not undergone profound deterioration. Reports indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine hydrochloride, the better the prognosis. Poor Perfusion of Vital Organs Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or comatose condition. Loss of pallor, increase in toe temperature and/or adequ…

Dosage & Administration

DOSAGE AND ADMINISTRATION Rate of Administration Dopamine Hydrochloride and 5% Dextrose Injection, USP is administered intravenously through a suitable intravenous catheter or needle. An IV drip chamber or other suitable metering device is essential for controlling the rate of flow in drops/minute. Each patient must be individually titrated to the desired hemodynamic and/or renal response with dopamine hydrochloride. In titrating to the desired increase in systolic blood pressure, the optimum dosage rate for renal response may be exceeded, thus necessitating a reduction in rate after the hemodynamic condition is stabilized. Administration of dopamine hydrochloride at rates greater than 50 mcg/kg/min has safely been used in advanced circulatory decompensation states. If unnecessary fluid expansion is of concern, use of a more concentrated solution may be preferred over increasing the flow rate of a less concentrated solution. Suggested Regimen When appropriate, increase blood volume with whole blood, plasma, or plasma expanders until central venous pressure is 10 to 15 cm H2O or pulmonary wedge pressure is 14 to 18 mm Hg. Begin infusion of Dopamine Hydrochloride and 5% Dextrose Inje…

Warnings

WARNINGS Patients who have been treated with monoamine oxidase (MAO) inhibitors prior to the administration of dopamine hydrochloride will require substantially reduced dosage. See Drug Interactions , below. Evidence is inadequate for fully defining proper dosage and limitations for use in children. Contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Do not add Dopamine Hydrochloride and 5% Dextrose Injection, USP to any alkaline diluent solution since dopamine hydrochloride is inactivated in alkaline solution. Solutions containing dextrose should not be administered through the same administration set as blood, as this may result in pseudoagglutination or hemolysis. The intravenous administration of solutions may cause fluid overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excess admin…

Contraindications

CONTRAINDICATIONS Dopamine hydrochloride should not be used in patients with pheochromocytoma. Dopamine hydrochloride should not be administered in the presence of uncorrected tachyarrhythmias or ventricular fibrillation. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Drug Interactions

Drug Interactions Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine. This interaction appears to be related both to pressor activity and to the beta-adrenergic stimulating properties of these catecholamines, and may produce ventricular arrhythmias. Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics. Results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol. Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine. Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine should receive initial doses of dopamine hydrochloride no greater than one-tenth (1/10) of the usual dose. Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow. Tricyclic …

Adverse Reactions

ADVERSE REACTIONS The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency. Cardiovascular System ventricular arrhythmia atrial fibrillation ectopic beats tachycardia anginal pain palpitation cardiac conduction abnormalities widened QRS complex bradycardia hypotension hypertension vasoconstriction Respiratory System dyspnea Gastrointestinal System nausea vomiting Metabolic/Nutritional System azotemia Central Nervous System headache anxiety Dermatological System piloerection Other Gangrene of the extremities has occurred when high doses were administered for prolonged periods or in patients with occlusive vascular disease receiving low doses of dopamine HCl.

Frequently Asked Questions

What is Dopamine Hydrochloride and Dextrose used for?

Dopamine Hydrochloride and Dextrose contains Dopamine Hydrochloride. It is a injection, solution taken intravenous. Consult your doctor for specific uses.

Is Dopamine Hydrochloride and Dextrose a controlled substance?

Dopamine Hydrochloride and Dextrose is not classified as a controlled substance by the DEA.

What is the generic name for Dopamine Hydrochloride and Dextrose?

The generic name for Dopamine Hydrochloride and Dextrose is Dopamine Hydrochloride. There are 12 other brand versions of Dopamine Hydrochloride.

What is the NDC code for Dopamine Hydrochloride and Dextrose 320 mg/100mL?

The NDC (National Drug Code) for Dopamine Hydrochloride and Dextrose 320 mg/100mL is 0338-1009, listed by Baxter Healthcare Corporation.

Product NDC

0338-1009

Package NDC

0338-1009-02

Other Dopamine Brands

See all →

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)